Cortisol in the Treatment of Phobias

This study is currently recruiting participants.

Verified by University of Zurich, March 2007

Sponsors and Collaborators:	University of Zurich University Hospital, Basel, Switzerland
Information provided by:	University of Zurich
ClinicalTrials.gov Identifier:	NCT00451750

Purpose

The aim of this prospective, double-blind, placebo-controlled, randomized study is to investigate if glucocorticoid treatment, in combination with exposure therapy, helps to reduce phobic fear in patients with phobia.

Condition	Intervention
Phobia	Drug: Cortisol

MedlinePlus related topics: Phobias

Drug Information available for: Hydrocortisone Cortisol 21-phosphate Cortisol succinate Hydrocortamate Hydrocortisone 21-sodium succinate Hydrocortisone acetate Hydrocortisone cypionate Hydrocortisone hemisuccinate Proctofoam-HC

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study
Official Title:	The Efficacy of Cortisol in Combination With Behavioral Therapy in the Treatment of Phobias

Eligibility

Ages Eligible for Study:	18 Years to 55 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

- Female and male patients with a specific phobia (fear of heights) according to DSM-IV criteria.

Exclusion Criteria:

Severe acute or chronic somatic diseases
Psychiatric disorder other than specific phobia
Topic glucocorticoid therapy (for large skin parts)
Inhaled glucocorticoids
Psychotropic medication
Pregnancy

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00451750

Contacts

Contact: Frank Wilhelm, Professor

+41 61 267 0593

frank.wilhelm@unibas.ch

Locations

Switzerland
University of Basel	Recruiting
Basel, Switzerland, 4055
Contact: Frank Wilhelm, Professor +41 61 267 0593 frank.wilhelm@unibas.ch

Sponsors and Collaborators

University of Zurich

University Hospital, Basel, Switzerland

Investigators

Principal Investigator:	Dominique JF de Quervain, MD, Prof.	University of Zürich
Principal Investigator:	Frank Wilhelm, Prof.	University Hospital, Basel, Switzerland

More Information

Publications:

Soravia LM, Heinrichs M, Aerni A, Maroni C, Schelling G, Ehlert U, Roozendaal B, de Quervain DJ. Glucocorticoids reduce phobic fear in humans. Proc Natl Acad Sci U S A. 2006 Apr 4;103(14):5585-90. Epub 2006 Mar 27.

Study ID Numbers:	2007DR3069
Study First Received:	March 21, 2007
Last Updated:	March 21, 2007
ClinicalTrials.gov Identifier:	NCT00451750
Health Authority:	Switzerland: Swissmedic; Switzerland: Ethical committee, Zürich Switzerland

Keywords provided by University of Zurich:

phobia
cortisol
memory
treatment

Study placed in the following topic categories:

Hydrocortisone
Cortisol succinate
Anxiety Disorders

Mental Disorders
Hydrocortisone acetate
Phobic Disorders

Additional relevant MeSH terms:

Anti-Inflammatory Agents
Therapeutic Uses
Pharmacologic Actions

ClinicalTrials.gov processed this record on January 14, 2009